MACS2 has been used in PCa to identify chromatin regions that are altered upon the acquisition of ENZA-resistance and enabled the selection of the appropriate therapy to target ENZA-resistant CRPC [321]. This evidence concerns the gene ACSM2A and posterior cortical atrophy.